Finding the right diagnosis with liver biopsy

The popularity of noninvasive options to diagnose liver disease has been growing, but are there times when more traditional methods like liver biopsy are still needed for a precise diagnosis?

Medical University of South Carolina hepatologist and researcher Don Rockey, M.D., and his team recently set out to answer that question. They examined 80 patients with a variety of suspected liver issues. Their goal was to understand the importance of biopsy in reaching the correct diagnosis. They report their study’s findings in an article published online in December in the Journal of Clinical Gastroenterology.

“Our study shows that that biopsy continues to be valuable as part of our diagnostic arsenal,” said Rockey.

What is a biopsy?

A biopsy is simply the process of sampling a piece of tissue from a patient’s body to examine it closely for markers of disease.

For example, a liver biopsy can be performed if a doctor suspects something is wrong with a patient’s liver. In this case, a needle is inserted into the patient’s abdomen to extract a tiny portion of the liver. That sample of the liver is examined under a microscope to see if it contains any features that might indicate a certain disease or injury.

Biopsy is one tool in a large toolbox for diagnosing liver disease, which also includes imaging and blood tests.

However, as with many medical tests, there are risks associated with biopsy.

“It can cause bleeding and pain. There is even a small risk for severe bleeding,” said Rockey. “If the bleeding is severe, death can even occur, but that's very, very uncommon – one in 5,000 to one in 10,000. By comparison, it's certainly not as risky as having a major surgery, but there is some risk.”

These risks cause some doctors to shy away from biopsies.

Despite the risks, Rockey still recommends that providers consider liver biopsy in some circumstances.

“In the right time, the right place and the right patient, it’s valuable,” he said.

Biopsy’s place in diagnosis

Rockey and his team found that biopsy was often crucial to making the right diagnosis.

The diagnoses that patients received before their biopsies matched up with their biopsy results just under two-thirds of the time. In over a third of the cases, however, biopsy was essential to making the correct diagnosis.

The numbers varied by disease as well. Autoimmune hepatitis was the most difficult disease to diagnose without a biopsy, while liver fibrosis was diagnosed correctly more than two-thirds of the time, even in the absence of biopsy.

Surprisingly, six of the 80 study patients who were thought to have some kind of liver issue before their biopsy did not have a liver issue at all.

“I think biopsy is most valuable when there is some diagnostic dilemma,” Rockey said. “So when we're not sure about what the problem is, biopsy is indicated and very useful.”

In fact, Rockey suggests that patients advocate for their own biopsy when there is no clear diagnosis.

“Patients whose physicians say ‘You have abnormal liver functions or abnormal liver tests, and I don't know why’ should ask about biopsy,” Rockey suggested.

Rockey and his team are also investigating ways to limit the risk of biopsy. They are examining whether biopsy can be performed effectively via an endoscope while minimizing risk and pain. This new form of biopsy may make the procedure more accessible which, in Rockey’s estimation, is a very good thing.

“Biopsy is an important part of making a correct diagnosis for many patients,” he said.

# # #

About MUSC

Founded in 1824 in Charleston, MUSC is the state’s only comprehensive academic health system, with a unique mission to preserve and optimize human life in South Carolina through education, research and patient care. Each year, MUSC educates more than 3,200 students in six colleges – Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy – and trains more than 900 residents and fellows in its health system. MUSC brought in more than $298 million in research funds in fiscal year 2022, leading the state overall in research funding. MUSC also leads the state in federal and National Institutes of Health funding, with more than $220 million. For information on academic programs, visit musc.edu.

As the health care system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest-quality and safest patient care while educating and training generations of outstanding health care providers and leaders to serve the people of South Carolina and beyond. Patient care is provided at 16 hospitals (includes owned and equity stake), with approximately 2,700 beds and four additional hospital locations in development; more than 350 telehealth sites and connectivity to patients’ homes; and nearly 750 care locations situated in all regions of South Carolina. In 2022, for the eighth consecutive year, U.S. News & World Report named MUSC Health University Medical Center in Charleston the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.

MUSC has a total enterprise annual operating budget of $5.1 billion. The nearly 26,000 MUSC family members include world-class faculty, physicians, specialty providers, scientists, students, affiliates and care team members who deliver groundbreaking education, research, and patient care.